HIV Infections Clinical Trial
Official title:
Adapting to HIV Disease - A Family Intervention
This study will evaluate the effectiveness of the Family Intervention: Telephone Tracking (FITT) program in improving depression, coping, and family functioning in HIV-infected individuals and their caregivers.
Individuals who are newly diagnosed with HIV often experience a variety of social and
psychological problems, which can leave them depressed and unable to cope with their
disease. The complex financial, legal, and psychiatric issues that many HIV-infected
individuals must face can be stressful and can negatively affect their health; they may miss
doctors' appointments or fail to adhere to a strict HIV medication regimen. The combination
of stress and inconsistent medical care can affect the immune system and potentially worsen
HIV symptoms.
Because of the multitude of stressors associated with HIV, HIV-infected individuals often
rely on a network of family and friends for support; these caregivers, however, are often
overwhelmed by their caregiver roles. They may experience helplessness, fear, and depression
as a result of their added responsibilities. Family Intervention: Telephone Tracking (FITT)
is a telephone-based intervention program that assists in identifying problems and resolving
them through referrals to medical and community organizations that provide HIV-related
support and services. It is also an educational resource that provides information on the
many medical and psychological aspects of HIV infection. The main goal of FITT is to
alleviate stress in both the HIV-infected individual and their support network by providing
information and resources to help cope with HIV. The purpose of this study is to evaluate
the effectiveness of FITT in improving family functioning, enhancing coping skills, and
reducing depression in HIV-infected individuals and their caregivers.
This 12-month study will enroll recently diagnosed HIV-infected individuals and one family
member or friend who is identified as their primary caregiver. Each pair will be randomly
assigned to either the FITT intervention group or to an assessment-only group that will not
receive FITT. Individuals who are assigned to receive FITT will utilize the service for
Months 1 through 6. HIV-infected participants in both groups will also receive regular
medical care throughout the study. Outcome measurements will include self-assessments of
depression, coping, and family functioning. In addition, participants receiving FITT will be
asked to evaluate the effectiveness of the telephone intervention. All measurements will be
assessed at baseline, and Months 3, 6, and 12.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |